 NEWARK, Calif., Nov. 14, 2022 GLOBE NEWSWIRE -- Rain Therapeutics Inc. NasdaqGS: RAIN, Rain a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwrights 3rd Annual Precision Oncology Conference on November 14, 2022. 